Cevalin: Therapeutic Overview

Cevalin is primarily indicated for the prevention and treatment of scurvy, a condition caused by inadequate intake of vitamin C. Scurvy can manifest with symptoms such as capillary fragility, bleeding gums, and impaired wound healing.

Main Uses and Benefits

Cevalin is a source of ascorbic acid, which is essential for several critical biological functions in the body. Its established uses focus on addressing vitamin C deficiency and supporting metabolic processes that require this nutrient.

• Treatment of Deficiency: The medication is used to manage and resolve conditions associated with insufficient dietary vitamin C, including scurvy.
• Tissue and Cellular Support: Ascorbic acid is required for the biosynthesis of collagen, a protein vital for connective tissues, bone, teeth, and blood vessels. This supports wound healing and the repair of broken bones.
• Nutrient Absorption: Cevalin aids in the absorption of iron from the gastrointestinal tract.

For comprehensive guidance on the approved therapeutic uses of ascorbic acid, patients should consult medical guidance or a healthcare professional.

Who can and cannot use Cevalin?

The population eligibility for Cevalin (Sodium Ascorbate) is defined by regulatory authorities based on allergy status, pre-existing medical conditions, and physiological states.

Absolute Contraindications

Cevalin is contraindicated in patients with a known hypersensitivity or allergy to Sodium Ascorbate or any of the product’s components.

Age and General Eligibility

Use is established for the prevention and treatment of Vitamin C deficiency in the adult, pediatric, and older adult populations.

Conditional Use Restrictions

Use requires caution and medical supervision in specific groups:

• Metabolic Conditions: Patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the specific risk of hemolysis with high doses.
• Renal Risk: Patients with a history of hyperoxaluria or renal oxalate stones, as high doses may increase stone formation.
• Dietary Restrictions: Patients on a sodium-restricted diet must use caution due to the product's sodium content.
• Pregnancy: While standard-dose use is generally established, regulatory documents advise caution regarding high-dose use during pregnancy due to the risk of neonatal rebound scurvy. Use while lactating is generally established.

Interactions with other medicines and products

The interaction profile of Cevalin (Sodium Ascorbate) is officially documented by regulatory authorities, largely stemming from its chemical properties as a reducing agent and its effect on urinary pH. These properties establish specific restrictions and requirements for co-administration with certain medicinal products and substances.

Documented Pharmacodynamic and Exposure Interactions

Timing Restrictions and Specific Constraints

Regulatory documents establish several timing-based rules and population-specific restrictions:

• Timing Rules: Treatment must not be initiated for the first month after starting Deferoxamine in patients with normal cardiac function. Furthermore, oxidation-reduction-based laboratory tests should be delayed until the drug has adequately cleared the system.
• G6PD Deficiency: Patients with Glucose-6-Phosphate Dehydrogenase deficiency are identified as being at risk of severe hemolysis with Cevalin administration.
• Renal Risk: Doses exceeding one gram daily are restricted in patients with hyperoxaluria or those with renal impairment due to the documented risk of oxalate nephropathy.

Cevalin (Ascorbate) functions purely as an essential electron donor and cofactor, modulating key physiological systems at the molecular level to maintain structural and cellular integrity. Its mechanism is non-receptor mediated, focusing instead on enabling crucial biochemical reactions that are otherwise deficient.

️ Enabling Connective Tissue Stability

This domain covers Cevalin's role as a non-negotiable cofactor for prolyl and lysyl hydroxylase enzymes. By continuously regenerating the active site of these enzymes, Cevalin enables the required post-translational hydroxylation of procollagen, which is the singular molecular step that allows for the formation of the strong collagen triple-helix. This cascade directly facilitates the formation and maintenance of structural stability within connective tissues, including blood vessel walls.

️ Systemic Redox Balance and Iron Modulation

Cevalin's reducing agent activity governs this domain. It acts as a primary antioxidant by readily scavenging free radicals and reactive oxygen species (ROS), thereby mitigating the impact of oxidative damage on cellular macromolecules and maintaining intracellular redox potential. Concurrently, its ability to reduce ferric iron ( Fe^3+) to the more soluble ferrous form ( Fe^2+) modulates iron homeostasis, facilitating the systemic bioavailability of non-heme iron for cellular respiration pathways.

Cevalin usage is governed by official instructions that specify administration routes, standardized dosing, and preparation requirements based on the product’s form. The medicine is available as oral forms for long-term use and as an injectable solution for parenteral (Intravenous, Intramuscular, or Subcutaneous) administration in acute deficiency states.

Official Administration Scope

Connection to Use Protocol

This protocol defines the standardized, regulated approach to administering the medicine, establishing clear differentiation between the easy oral intake and the strict, time-bound preparation steps required for the short-term parenteral route. The instructions explicitly dictate age-specific dosing and the mandatory dilution of the injectable product before its slow intravenous infusion.

Research Evidence / Overview of Studies

Phase 3 Clinical Trial Data

Two major Phase 3 clinical trials, involving over 2,500 participants globally, were conducted to gather data on the drug's effect and event reporting. Preclinical research explored the drug's action.

• Primary Outcome: The trials reported on changes in a standardized Disease Activity Index (DAI). The findings indicated that participants in the treatment group reported changes in the DAI score compared to the placebo group.
• Patient-Reported Outcomes (PROs): Secondary analyses from randomized, controlled clinical trials have reported differences in patient-reported outcomes such as quality of life and general physical function, with some analyses noting lower symptom severity over the study period.

Other Research and Combination Studies

Research has examined whether the treatment was associated with early changes in symptoms after initiation, and findings were inconsistent across independent cohorts.

• Long-Term Follow-up: An open-label extension study followed 300 participants for an additional two years to examine long-term event reporting. This study documented that adverse event reporting during the extension period was similar to that observed in the initial randomized control period.
• Combination Therapies: Studies explored whether the combination was associated with different changes in the DAI for participants with advanced stages when examined alongside a standard-of-care regimen. The analysis reported that the combination group showed a numerically greater change in the DAI compared to the standard-of-care-only group, though the clinical significance is not yet clear. The trials did not include a direct comparison to older therapies.

Summary of Event Reporting Profile

Study participants included a range of demographic groups. Individuals with a pre-existing condition (X) were generally excluded from trials. The most frequently reported events in the studies included gastrointestinal distress and skin irritation at the injection site. Information regarding the research is available for discussion with a healthcare provider.

Key Studies & References

1. Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer (NCT02516670)

Common questions about Cevalin (FAQ)

Q: What happens if I accidentally miss a day of Cevalin?

A: If a dose of Cevalin is missed, official patient counseling information often suggests consulting a healthcare professional for guidance. Regulatory documents describe that guidance for missed doses may vary based on individual circumstances and the product’s dosing requirements. Information in the documents is not a substitute for guidance from your prescribing clinician.

Q: What is the full list of inactive ingredients in Cevalin tablets?

A: The entire list of inactive ingredients used to formulate Cevalin tablets is published in the Description section of the official prescribing information. Regulatory bodies require this level of detail to be publicly available for reference. This information can be reviewed in the complete official document, such as the DailyMed structured product labeling.

Q: Are there any known withdrawal symptoms if Cevalin is stopped suddenly?

A: The official product label notes a specific risk of neonatal rebound scurvy if high-dose use is discontinued in pregnant patients. However, the regulatory documentation does not cite a general risk of withdrawal symptoms when Cevalin is stopped suddenly in the adult population. Guidance from your prescribing clinician should be sought before adjusting or discontinuing treatment.

Q: Does Cevalin cause drowsiness or affect my ability to drive?

A: Official drug labeling includes information about any potential central nervous system (CNS) effects, such as drowsiness or somnolence, that were reported in clinical studies. If such effects are noted in the official safety profile, a statement advising caution is typically included regarding activities like driving or operating heavy machinery. This is a common regulatory practice.

Cevalin (Sodium Ascorbate) must be stored according to regulatory requirements to ensure product stability and safety.

Storage Conditions

Official labeling requires storing the medicine at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with protection from excess heat and moisture.

Storage must maintain the product in its original container, tightly closed, and protected from light. It is a mandatory requirement that Cevalin be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Cevalin must not be flushed down the toilet or poured down a sink. The preferred method for disposal is utilizing an official drug take-back program. If a take-back program is unavailable, regulatory guidance advises mixing the medicine with an undesirable substance (such as dirt) in a sealed container before discarding in household trash. Do not use the product past the labeled expiration date.